Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300150 · ClinicalTrials.gov registry record · Phase 1
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by PAQ Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
- 5
- Study locations
NCT07300150 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by PAQ Therapeutics. The registered enrollment target is 195 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT07300150, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by PAQ Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG PT0511
Study Locations (5)
Texas
- New Experimental Therapeutics of San Antonio LLC - San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC - San Antonio
Massachusetts
- Dana-Farber/Massachusetts General Hospital, Inc - Boston
Utah
- START Mountain Region - West Valley City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2028-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07300150
The ClinicalTrials.gov registry entry for NCT07300150 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (70% lower). The listed sponsor is PAQ Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT07300150 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Massachusetts, Utah.
Frequently Asked Questions
What is clinical trial NCT07300150 about?
NCT07300150 is a clinical study titled "A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors". The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal canc...
What is the current status of trial NCT07300150?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2025-11-21. Estimated completion is 2028-10-18.
What conditions does trial NCT07300150 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor.
What interventions are being tested in trial NCT07300150?
The interventions under investigation include: Cetuximab (DRUG), PT0511 (DRUG).
Who is sponsoring clinical trial NCT07300150?
This trial is sponsored by PAQ Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300150 being conducted?
This trial has 5 study locations across Massachusetts, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.